In April 2025, Novo announced an additional investment of more than $1 billion to expand its production site in Montes Claros, Minas Gerais, Brazil, with operations expected to begin in 2028
Association between Different GLP-1 Receptor Agonists and Gastrointestinal Adverse Reactions: A Real-World Disproportionality Study Based on FDA Adverse Event Reporting System Database. Frontiers in Endocrinology, vol
Over time, the body adjusts, but diet changes may be needed
Handling and Laboratory Safety Working with research peptides GLP-1 requires a sterile environment to prevent the introduction of proteases
Nr fundamentet er i orden, bliver underholdningen bde mere afslappet og mere tilfredsstillende, og du kan fokusere p det, der virkelig tller: at spille ansvarligt og have det sjovt
GLP-1 medications arent specifically approved for use during breastfeeding